PURPOSE: This study focused on circulating levels of vascular endothelial growth factor in patients with prostate cancer compared to a normal population. METHODS: We analyzed 26 normal individuals and 80 patients with prostate cancer. Blood was drawn from all subjects, and plasma was extracted to determine the concentration of vascular endothelial growth factor using a quantitative immunoassay technique (ELISA-enzyme-linked immunosorbent assay). RESULTS: The median plasma level of vascular endothelial growth factor was significantly elevated in patients with metastatic disease compared to patients with localized disease and with healthy controls. Patients with serum prostate-specific antigen > 20 ng/mL had significantly higher levels of plasma vascular endothelial growth factor than patients with serum prostate-specific antigen < 20 ng/mL. There was a trend for patients with a Gleason score of 8 to 10 to have higher levels of plasma vascular endothelial growth factor when compared to patients with lower Gleason scores. No relationship was found between plasma vascular endothelial growth factor and clinical staging, or between plasma vascular endothelial growth factor and prostate volume, in patients with localized prostate cancer. CONCLUSION: This study indicates that patients with metastatic prostate cancer have higher plasma vascular endothelial growth factor levels than patients with localized disease or in healthy controls.
PURPOSE: This study focused on circulating levels of vascular endothelial growth factor in patients with prostate cancer compared to a normal population. METHODS: We analyzed 26 normal individuals and 80 patients with prostate cancer. Blood was drawn from all subjects, and plasma was extracted to determine the concentration of vascular endothelial growth factor using a quantitative immunoassay technique (ELISA-enzyme-linked immunosorbent assay). RESULTS: The median plasma level of vascular endothelial growth factor was significantly elevated in patients with metastatic disease compared to patients with localized disease and with healthy controls. Patients with serum prostate-specific antigen > 20 ng/mL had significantly higher levels of plasma vascular endothelial growth factor than patients with serum prostate-specific antigen < 20 ng/mL. There was a trend for patients with a Gleason score of 8 to 10 to have higher levels of plasma vascular endothelial growth factor when compared to patients with lower Gleason scores. No relationship was found between plasma vascular endothelial growth factor and clinical staging, or between plasma vascular endothelial growth factor and prostate volume, in patients with localized prostate cancer. CONCLUSION: This study indicates that patients with metastatic prostate cancer have higher plasma vascular endothelial growth factor levels than patients with localized disease or in healthy controls.
Authors: Philip J Saylor; Kevin R Kozak; Matthew R Smith; Marek A Ancukiewicz; Jason A Efstathiou; Anthony L Zietman; Rakesh K Jain; Dan G Duda Journal: Oncologist Date: 2012-02-02
Authors: Jianqing Lin; Tingting Zhan; Danielle Duffy; Jean Hoffman-Censits; Deborah Kilpatrick; Edouard J Trabulsi; Costas D Lallas; Inna Chervoneva; Kimberly Limentani; Brooke Kennedy; Sarah Kessler; Leonard Gomella; Emmanuel S Antonarakis; Michael A Carducci; Thomas Force; Wm Kevin Kelly Journal: Am J Cancer Ther Pharmacol Date: 2014-09-07
Authors: William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Rana R McKay; Amado J Zurita; Lillian Werner; Justine Y Bruce; Michael A Carducci; Mark N Stein; Elisabeth I Heath; Arif Hussain; Hai T Tran; Christopher J Sweeney; Robert W Ross; Philip W Kantoff; Susan F Slovin; Mary-Ellen Taplin Journal: J Clin Oncol Date: 2016-04-04 Impact factor: 44.544
Authors: A Mavrou; K Brakspear; M Hamdollah-Zadeh; G Damodaran; R Babaei-Jadidi; J Oxley; D A Gillatt; M R Ladomery; S J Harper; D O Bates; S Oltean Journal: Oncogene Date: 2014-11-10 Impact factor: 9.867